Achilles Therapeutics

71 articles about Achilles Therapeutics

• Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

  4/4/2024

  Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

• Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

  4/4/2024

  Achilles Therapeutics plc announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.

• Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

  2/5/2024

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference.

• Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

  12/18/2023

  Achilles Therapeutics plc today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward.

• Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

  11/13/2023

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

• Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

  9/22/2023

  Achilles Therapeutics plc disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.

• Achilles Therapeutics to Present at Upcoming June 2023 Conferences

  6/12/2023

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, announced that the Company will be taking part in the following conferences in June.

• Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

  5/10/2023

  Achilles Therapeutics plc announced that the Company’s new AI application, trained with proprietary real-world data, outperformed current AI and non-AI state-of-the-art methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies.

• Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

  5/10/2023

  Achilles Therapeutics plc today announced its financial results for the first quarter ended March 31, 2023, and recent business highlights.

• Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

  4/25/2023

  Achilles Therapeutics plc today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market.

• Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

  4/25/2023

  Achilles Therapeutics plc today announced that United States (US) patent 11,634,773 has been granted.

• Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

  4/17/2023

  Achilles Therapeutics plc today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Operations, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023, at 11:30am ET / 4:30pm UK.

• Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

  3/7/2023

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights.

• Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/20/2022

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST.

• Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

  12/6/2022

  Achilles Therapeutics plc today presented an encouraging interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma at the ESMO Immuno-Oncology Congress 2022 (ESMO IO).  

• Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

  11/30/2022

  Achilles Therapeutics plc (NASDAQ: ACHL) today announced that an abstract highlighting updated interim results from the ongoing Phase I/IIa CHIRON and THETIS clinical trials evaluating clonal neoantigen-reactive T cells (cNeT) has been accepted for a poster presentation at the ESMO Immuno-Oncology Annual Congress (ESMO IO) taking place in Geneva, Switzerland from December 7-9, 2022.

• Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

  11/22/2022

  Achilles Therapeutics plc today announced that United States (US) patent 11,504,398 has been granted.

• Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

  11/8/2022

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and recent business highlights.

• Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

  10/6/2022

  Achilles Therapeutics plc today announced that its Co-founder Charles Swanton, MD, PhD, FRS, FRCP from the Francis Crick Institute & UCL, and Scientific Advisory Board member Christopher Klebanoff from Memorial Sloan Kettering will join John Haanen, MD from the Netherlands Cancer Institute on a Neoantigen Expert Roundtable to discuss the importance of neoantigens as targets in solid tumor cell therapy.

• Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

  7/21/2022

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that it is leading a consortium that has been awarded a €4 million grant from Horizon Europe, the European Union’s key funding program for research and innovation.